Servicio de Cardiología, Unidad de Imagen Cardiaca, Unidad de Cardio-Oncología, Hospital Universitario La Paz, IdiPaz, Madrid, Spain.
Peter Munk Cardiac Center, Ted Rogers Program in Cardiotoxicity Prevention, Toronto General Hospital, University Health Network, University of Toronto, Toronto, Canada.
Rev Esp Cardiol (Engl Ed). 2017 Jun;70(6):487-495. doi: 10.1016/j.rec.2017.01.004. Epub 2017 Feb 8.
The undeniable advances in the field of oncology have finally led to a decrease in overall cancer-related mortality. However, this population of long-term cancer survivors is now facing a shift toward a substantial increase in cardiovascular morbidity and mortality. Because the development of overt cardiotoxicity can be associated with poor outcomes, preclinical identification of cardiac toxicity is important. This will promote early instauration of treatments to prevent overt heart dysfunction and allow oncologists to continue cancer therapy in an uninterrupted manner. Surveillance strategies for the early detection of cardiac injury include cardiac imaging and biomarkers during treatment. In this review, we outline existing cardiac imaging modalities to detect myocardial changes in patients undergoing cancer treatment and in survivors, and their strengths and limitations.
肿瘤学领域不可否认的进展最终导致了癌症相关总体死亡率的下降。然而，这群长期癌症幸存者现在正面临着心血管疾病发病率和死亡率大幅上升的转变。由于明显的心脏毒性的发生可能与不良预后相关，因此心脏毒性的临床前识别很重要。这将促进早期采取治疗措施以预防明显的心脏功能障碍，并使肿瘤学家能够不间断地继续癌症治疗。早期检测心脏损伤的监测策略包括治疗期间的心脏成像和生物标志物。在本综述中，我们概述了现有的心脏成像模式，以检测接受癌症治疗的患者及其幸存者的心肌变化，以及它们的优缺点。
